erythrosine has been researched along with razoxane in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boehme, P; Gordeuk, VR; John, C; Loyevsky, M; Sacci, JB; Weglicki, W | 1 |
| Barnabé, N; Hasinoff, BB; Venkataram, S; Zastre, JA | 1 |
| Hasinoff, BB | 1 |
| Hasinoff, BB; Schroeder, PE | 1 |
| Draenert, GF; Huetzen, DO; Kämmerer, PW; Nacu, V; Palarie, V; Wagner, W | 1 |
5 other study(ies) available for erythrosine and razoxane
| Article | Year |
|---|---|
Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Deferoxamine; Erythrocytes; Ethylenediamines; Ferrous Compounds; Fluoresceins; Fluorescent Dyes; Glycine; Humans; Iron Chelating Agents; Liver; Malaria, Falciparum; Mice; Microscopy, Fluorescence; Parasitemia; Plasmodium falciparum; Plasmodium yoelii; Prodrugs; Quaternary Ammonium Compounds; Razoxane; Spectrometry, Fluorescence; Surface Properties | 1999 |
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cell Survival; Cells, Cultured; Deferiprone; Doxorubicin; Electron Spin Resonance Spectroscopy; Fluoresceins; Free Radicals; Indicators and Reagents; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Myocytes, Cardiac; Oxidation-Reduction; Pyridones; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure | 2002 |
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane | 2002 |
Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cell Culture Techniques; Cell Line; Cell Shape; Cell Survival; Collagen; Coloring Agents; Cytoprotection; Diphosphonates; Drug Carriers; Durapatite; Female; Fibroblasts; Fluoresceins; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Models, Animal; Osteoblasts; Osteogenesis; Protective Agents; Rabbits; Razoxane; Tetrazolium Salts; Thiazoles; Tibia; Zoledronic Acid | 2012 |